Treatment with the bile acid sequestrant colesevelam increases GLP-1 secretion and improves glycemia in ob/ob mice in an FXR-dependent manner, thus confirming that the FXR/GLP-1 pathway is a new mechanism for bile acids to control glucose metabolism and a pharmacological target for type 2 diabetes (Trabelsi et al., 2015). The gene discussed is NR1H4; the disease is type 2 diabetes mellitus.